Validation of a multiplex genotyping platform using a novel genomic database approach.

Area of Science:

• Genomics
• Genetic screening
• Molecular diagnostics

Background:

• Multiplex platforms enable simultaneous testing for numerous genetic conditions.
• Traditional validation methods using known samples or synthetic plasmids have limitations, especially for rare diseases.
• Novel genomic databases offer new possibilities for validating genetic assays.

Purpose of the Study:

• To validate an expanded genetic carrier screening platform using a novel genomic database.
• To assess the platform's performance in detecting a wide range of genetic diseases and mutations.
• To address the limitations of traditional validation methods in the context of rare genetic conditions.

Main Methods:

• Utilized the Illumina Infinium iSelect HD Custom genotyping platform for an expanded carrier screening assay.
• Tested for 213 genetic diseases by analyzing 1,663 pathogenic mutations.
• Leveraged Coriell Institute biorepositories, including the Subcollection of Heritable Diseases and the 1000 Genomes Project, for validation.

Main Results:

• Analyzed 12,394 mutation observations across 206 samples.
• Achieved 246 true positives, 12,147 true negatives, 1 false positive, and 0 false negatives.
• Demonstrated exceptional performance with 99.99% sensitivity and 99.99% specificity.

Conclusions:

• Successfully validated the expanded genetic carrier screening platform using biorepository samples.
• Confirmed high sensitivity and specificity, indicating reliable performance.
• Highlighted the value of the 1000 Genomes Project for validating mutations in genes not covered by other resources, enhancing validation depth.